Aims
The definition of sarcopenia based on appendicular lean mass/height (2) (ALM/height (2)) is often used, although it can underestimate the prevalence of sarcopenia in overweight/obese patients with heart failure. Therefore, new methods have been proposed to overcome this limitation. We aimed to evaluate the prevalence of sarcopenia by three methods and compare body composition in this population.
Methods and results
We enrolled 168 male patients with heart failure (left ventricular ejection fraction <40%). Sixty‐six patients (39.3%) were identified with sarcopenia by at least one method. The lower 20th percentile defined as the cut‐off point for sarcopenia was 7.03 kg/m2, −2.32 and 0.76 for Baumgartner's (20.8%), Newman's (21.4%), and Studenski's methods (21.4%), respectively. Patients with body mass index (BMI) <25 kg/m2 were more likely to be identified by Baumgartner's than Studenski's method (P < 0.001). However, in patients with BMI ≥ 25 kg/m2, Studenski's and Newman's methods were more likely to detect sarcopenia than Baumgartner's method (both P < 0.005). Patients were further divided into three subgroups: (i) patients classified in all indexes (n = 8), (ii) patients classified in Baumgartner's (sarcopenic; n = 27), and (iii) patients classified in both Newman's and Studenski's methods (sarcopenic obesity; n = 31). Comparing body composition among groups, all sarcopenic groups presented lower total lean mass compared with non‐sarcopenic patients, whereas sarcopenic obese patients had higher total lean mass than lean sarcopenic patients.
Conclusions
Our results demonstrate that the prevalence of sarcopenia in overweight/obese patients is similar to lean sarcopenic patients when other methods are considered. In patients with higher BMI, Studenski's method seems to be more feasible to detect sarcopenia.
BackgroundTestosterone deficiency in patients with heart failure (HF) is associated with
decreased exercise capacity and mortality; however, its impact on hospital
readmission rate is uncertain. Furthermore, the relationship between testosterone
deficiency and sympathetic activation is unknown.ObjectiveWe investigated the role of testosterone level on hospital readmission and
mortality rates as well as sympathetic nerve activity in patients with HF.MethodsTotal testosterone (TT) and free testosterone (FT) were measured in 110
hospitalized male patients with a left ventricular ejection fraction < 45% and
New York Heart Association classification IV. The patients were placed into low
testosterone (LT; n = 66) and normal testosterone (NT; n = 44) groups.
Hypogonadism was defined as TT < 300 ng/dL and FT < 131 pmol/L. Muscle
sympathetic nerve activity (MSNA) was recorded by microneurography in a
subpopulation of 27 patients.ResultsLength of hospital stay was longer in the LT group compared to in the NT group (37
± 4 vs. 25 ± 4 days; p = 0.008). Similarly, the cumulative hazard of readmission
within 1 year was greater in the LT group compared to in the NT group (44% vs.
22%, p = 0.001). In the single-predictor analysis, TT (hazard ratio [HR], 2.77;
95% confidence interval [CI], 1.58–4.85; p = 0.02) predicted hospital readmission
within 90 days. In addition, TT (HR, 4.65; 95% CI, 2.67–8.10; p = 0.009) and
readmission within 90 days (HR, 3.27; 95% CI, 1.23–8.69; p = 0.02) predicted
increased mortality. Neurohumoral activation, as estimated by MSNA, was
significantly higher in the LT group compared to in the NT group (65 ± 3 vs. 51 ±
4 bursts/100 heart beats; p < 0.001).ConclusionThese results support the concept that LT is an independent risk factor for
hospital readmission within 90 days and increased mortality in patients with HF.
Furthermore, increased MSNA was observed in patients with LT.
During muscle mechanoreflex activation (isometric exercise), AASU have normal MSNA and FBF responses, whereas during central command (mental stress) stimulation, AASU have exacerbated MSNA and blunted vasodilation. Therefore, mental stress seems to exacerbate neurovascular control throughout stress reaction situations in AASU.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.